Progyny, Inc. (NASDAQ:PGNY - Get Free Report) Chairman David J. Schlanger sold 1,000 shares of the company's stock in a transaction that occurred on Monday, April 1st. The shares were sold at an average price of $37.52, for a total transaction of $37,520.00. Following the completion of the transaction, the chairman now owns 83,631 shares of the company's stock, valued at approximately $3,137,835.12. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.
Progyny Trading Up 0.2 %
NASDAQ PGNY opened at $35.75 on Thursday. The firm's fifty day moving average price is $37.81 and its two-hundred day moving average price is $35.65. Progyny, Inc. has a 1 year low of $29.44 and a 1 year high of $44.95. The firm has a market capitalization of $3.45 billion, a P/E ratio of 57.66, a price-to-earnings-growth ratio of 1.47 and a beta of 1.48.
Progyny (NASDAQ:PGNY - Get Free Report) last posted its quarterly earnings results on Tuesday, February 27th. The company reported $0.13 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.09 by $0.04. Progyny had a net margin of 5.70% and a return on equity of 12.64%. The firm had revenue of $269.94 million for the quarter, compared to analyst estimates of $274.08 million. During the same period in the prior year, the firm posted $0.03 earnings per share. The company's quarterly revenue was up 26.0% compared to the same quarter last year. On average, research analysts anticipate that Progyny, Inc. will post 0.7 EPS for the current fiscal year.
Wall Street Analysts Forecast Growth
Have You Seen Elon’s New A.I. Device? (Picture Inside)
From InvestorPlace | Ad
A strange new era for mankind is upon us...
And it's all thanks to Elon Musk's latest creation. Click here to see this strange device you could be wearing some day.
Elon believes A.I. is advancing so fast...
This strange new device to protect us against that A.I. threat...
Several research firms have recently weighed in on PGNY. SVB Leerink began coverage on shares of Progyny in a report on Monday, February 26th. They issued an "outperform" rating and a $49.00 price target for the company. Leerink Partnrs reiterated an "outperform" rating on shares of Progyny in a report on Monday, February 26th. Barclays initiated coverage on shares of Progyny in a report on Wednesday, January 3rd. They set an "overweight" rating and a $48.00 target price for the company. KeyCorp reduced their target price on shares of Progyny from $45.00 to $43.00 and set an "overweight" rating for the company in a report on Wednesday, February 28th. Finally, Truist Financial reduced their target price on shares of Progyny from $47.00 to $46.00 and set a "buy" rating for the company in a report on Wednesday, February 28th. Ten research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock currently has a consensus rating of "Buy" and a consensus price target of $48.30.
Read Our Latest Report on Progyny
Institutional Trading of Progyny
Several institutional investors and hedge funds have recently added to or reduced their stakes in PGNY. International Assets Investment Management LLC raised its position in shares of Progyny by 352,414.2% in the fourth quarter. International Assets Investment Management LLC now owns 5,876,411 shares of the company's stock valued at $218,485,000 after purchasing an additional 5,874,744 shares during the period. Millennium Management LLC raised its position in shares of Progyny by 240.1% in the fourth quarter. Millennium Management LLC now owns 875,136 shares of the company's stock valued at $27,260,000 after purchasing an additional 617,830 shares during the period. Vanguard Group Inc. raised its position in shares of Progyny by 7.4% in the third quarter. Vanguard Group Inc. now owns 8,157,604 shares of the company's stock valued at $277,522,000 after purchasing an additional 565,160 shares during the period. Jennison Associates LLC raised its position in shares of Progyny by 19.4% in the third quarter. Jennison Associates LLC now owns 2,706,454 shares of the company's stock valued at $92,074,000 after purchasing an additional 438,932 shares during the period. Finally, Wellington Management Group LLP bought a new position in shares of Progyny in the fourth quarter valued at about $14,608,000. 94.93% of the stock is owned by institutional investors.
Progyny Company Profile
(
Get Free Report)
Progyny, Inc, a benefits management company, specializes in fertility and family building benefits solutions in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
